Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 OMAHA-004 study of opevesostat versus investigator's choice of abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer after progression on one prior novel hormonal agent
CTR20240487Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of opevesostat, abiraterone, enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Merck & Co.. Started Apr 2024; status: active.
02
Drugs
opevesostatabirateroneenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20240487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240487.